| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
|
Medicine details |
|
| Medicine name | adalimumab (Humira®) |
| Formulation | 40 mg solution for injection |
| Reference number | 1382 |
| Indication | Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy |
| Company | AbbVie Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/09/2015 |
| NICE guidance | TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |